Billing Codes — Australian Health Schedule Tracker

Showing 5201–5250 of 6045 Pg 105/121

	Item No.	Description	Category	Schedule Fee	100% Benefit
	73333	Detection of germline mutations of the von Hippel‑Lindau (VHL) gene: (a) in a patient who has a clinical diagnosis of VHL syndrome and: (i) a family history of VHL syndrome and one of the following: (A) haemangioblastoma (retinal or central nervous system); (B) phaeochromocytoma; (C) renal cell carcinoma; or (ii) 2 or more haemangioblastomas; or (iii) one haemangioblastoma and a tumour or a cyst of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; or (E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or (b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome: (i) haemangiblastomas of the brain, spinal cord, or retina; (ii) phaeochromocytoma; (iii) functional extra‑adrenal paraganglioma Group P7	Category 6 — Pathology	$600.00	—
Item Number 73333 Schedule Fee $600.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2012 Item from: 01.11.2012 Gov. Change Flags No changes flagged Full Description Detection of germline mutations of the von Hippel‑Lindau (VHL) gene: (a) in a patient who has a clinical diagnosis of VHL syndrome and: (i) a family history of VHL syndrome and one of the following: (A) haemangioblastoma (retinal or central nervous system); (B) phaeochromocytoma; (C) renal cell carcinoma; or (ii) 2 or more haemangioblastomas; or (iii) one haemangioblastoma and a tumour or a cyst of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; or (E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or (b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome: (i) haemangiblastomas of the brain, spinal cord, or retina; (ii) phaeochromocytoma; (iii) functional extra‑adrenal paraganglioma Sign in to watch this code → Get an email alert when this item changes
	73334	Detection of germline mutations of the von Hippel-Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene Group P7	Category 6 — Pathology	$340.00	—
Item Number 73334 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2012 Item from: 01.11.2012 Gov. Change Flags No changes flagged Full Description Detection of germline mutations of the von Hippel-Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene Sign in to watch this code → Get an email alert when this item changes
	73335	Detection of somatic mutations of the von Hippel-Lindau (VHL) gene in a patient with: (a) 2 or more tumours comprising: (i) 2 or more haemangioblastomas, or (ii) one haemangioblastoma and a tumour of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; and (b) no germline mutations of the VHL gene identified by genetic testing Group P7	Category 6 — Pathology	$470.00	—
Item Number 73335 Schedule Fee $470.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2012 Item from: 01.11.2012 Gov. Change Flags No changes flagged Full Description Detection of somatic mutations of the von Hippel-Lindau (VHL) gene in a patient with: (a) 2 or more tumours comprising: (i) 2 or more haemangioblastomas, or (ii) one haemangioblastoma and a tumour of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; and (b) no germline mutations of the VHL gene identified by genetic testing Sign in to watch this code → Get an email alert when this item changes
	73336	A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled. Group P7	Category 6 — Pathology	$230.95	—
Item Number 73336 Schedule Fee $230.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.12.2013 Item from: 01.12.2013 Gov. Change Flags No changes flagged Full Description A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled. Sign in to watch this code → Get an email alert when this item changes
	73337	A test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) for epidermal growth factor receptor (EGFR) status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73438 applies Group P7	Category 6 — Pathology	$397.35	—
Item Number 73337 Schedule Fee $397.35 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.01.2014 Item from: 01.01.2014 Gov. Change Flags No changes flagged Full Description A test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) for epidermal growth factor receptor (EGFR) status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73438 applies Sign in to watch this code → Get an email alert when this item changes
	73338	A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if: (a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if: the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or a clinically-relevant RAS variant is detected; and, in cases where no RAS variant is detected (b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled. Group P7	Category 6 — Pathology	$362.60	—
Item Number 73338 Schedule Fee $362.60 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 22.08.2016 Item from: 01.04.2014 Gov. Change Flags No changes flagged Full Description A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if: (a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if: the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or a clinically-relevant RAS variant is detected; and, in cases where no RAS variant is detected (b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled. Sign in to watch this code → Get an email alert when this item changes
	73339	Detection of germline mutations in the RET gene in patients with a suspected clinical diagnosis of multiple endocrine neoplasia type 2 (MEN2) requested by a specialist or consultant physician who manages the treatment of the patient. One test. (Item is subject to rule 25) Group P7	Category 6 — Pathology	$400.00	—
Item Number 73339 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2014 Item from: 01.11.2014 Gov. Change Flags No changes flagged Full Description Detection of germline mutations in the RET gene in patients with a suspected clinical diagnosis of multiple endocrine neoplasia type 2 (MEN2) requested by a specialist or consultant physician who manages the treatment of the patient. One test. (Item is subject to rule 25) Sign in to watch this code → Get an email alert when this item changes
	73340	Detection of a known mutation in the RET gene in an asymptomatic relative of a patient with a documented pathogenic germline RET mutation requested by a specialist or consultant physician who manages the treatment of the patient. One test. (Item is subject to rule 25) Group P7	Category 6 — Pathology	$200.00	—
Item Number 73340 Schedule Fee $200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2014 Item from: 01.11.2014 Gov. Change Flags No changes flagged Full Description Detection of a known mutation in the RET gene in an asymptomatic relative of a patient with a documented pathogenic germline RET mutation requested by a specialist or consultant physician who manages the treatment of the patient. One test. (Item is subject to rule 25) Sign in to watch this code → Get an email alert when this item changes
	73341	Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is: (a) for ALK gene rearrangement status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73439 applies Group P7	Category 6 — Pathology	$400.00	—
Item Number 73341 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.07.2015 Item from: 01.07.2015 Gov. Change Flags No changes flagged Full Description Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is: (a) for ALK gene rearrangement status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73439 applies Sign in to watch this code → Get an email alert when this item changes
	73342	An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled. Group P7	Category 6 — Pathology	$315.40	—
Item Number 73342 Schedule Fee $315.40 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.01.2016 Item from: 01.01.2016 Gov. Change Flags No changes flagged Full Description An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled. Sign in to watch this code → Get an email alert when this item changes
	73343	Detection of 17p chromosomal deletions, in a patient with chronic lymphocytic leukaemia or small lymphocytic lymphoma, on a peripheral blood, bone marrow or lymph node sample, requested by a specialist or consultant physician For any particular patient: (a) at initial diagnosis; or (b) at disease relapse; or (c) on disease progression; but only where initiation of, or change in, therapy is anticipated Group P7	Category 6 — Pathology	$589.90	—
Item Number 73343 Schedule Fee $589.90 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2021 Item from: 01.09.2017 Gov. Change Flags No changes flagged Full Description Detection of 17p chromosomal deletions, in a patient with chronic lymphocytic leukaemia or small lymphocytic lymphoma, on a peripheral blood, bone marrow or lymph node sample, requested by a specialist or consultant physician For any particular patient: (a) at initial diagnosis; or (b) at disease relapse; or (c) on disease progression; but only where initiation of, or change in, therapy is anticipated Sign in to watch this code → Get an email alert when this item changes
	73344	Fluorescence in situ hybridization (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is: (a) for ROS1 gene arrangement status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73439 applies Group P7	Category 6 — Pathology	$400.00	—
Item Number 73344 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.01.2019 Item from: 01.01.2019 Gov. Change Flags No changes flagged Full Description Fluorescence in situ hybridization (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is: (a) for ROS1 gene arrangement status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73439 applies Sign in to watch this code → Get an email alert when this item changes
	73345	Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of investigating, making or excluding a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73347, 73348, or 73349 applies. The patient must have clinical or laboratory findings suggesting there is a high probability suggestive of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder. Group P7	Category 6 — Pathology	$500.00	—
Item Number 73345 Schedule Fee $500.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2018 Item from: 01.07.2018 Gov. Change Flags No changes flagged Full Description Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of investigating, making or excluding a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73347, 73348, or 73349 applies. The patient must have clinical or laboratory findings suggesting there is a high probability suggestive of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder. Sign in to watch this code → Get an email alert when this item changes
	73346	Testing of a pregnant patient whose carrier status for pathogenic cystic fibrosis transmembrane conductance regulator variants, as well as their reproductive partner carrier status is unknown, for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus, in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73350 applies. The fetus must have ultrasonic findings of echogenic gut, with unknown familial cystic fibrosis transmembrane conductance regulator variants. Group P7	Category 6 — Pathology	$500.00	—
Item Number 73346 Schedule Fee $500.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2018 Item from: 01.07.2018 Gov. Change Flags No changes flagged Full Description Testing of a pregnant patient whose carrier status for pathogenic cystic fibrosis transmembrane conductance regulator variants, as well as their reproductive partner carrier status is unknown, for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus, in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73350 applies. The fetus must have ultrasonic findings of echogenic gut, with unknown familial cystic fibrosis transmembrane conductance regulator variants. Sign in to watch this code → Get an email alert when this item changes
	73347	Testing of a prospective parent for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the risk of their fetus having pathogenic cystic fibrosis transmembrane conductance regulator variants. This is indicated when the fetus has ultrasonic evidence of echogenic gut when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73348, or 73349 applies. Group P7	Category 6 — Pathology	$500.00	—
Item Number 73347 Schedule Fee $500.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2018 Item from: 01.07.2018 Gov. Change Flags No changes flagged Full Description Testing of a prospective parent for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the risk of their fetus having pathogenic cystic fibrosis transmembrane conductance regulator variants. This is indicated when the fetus has ultrasonic evidence of echogenic gut when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73348, or 73349 applies. Sign in to watch this code → Get an email alert when this item changes
	73348	Testing of a patient with a laboratory-established family history of pathogenic cystic fibrosis transmembrane conductance regulator variants, for the purpose of determining whether the patient is an asymptomatic genetic carrier of the pathogenic cystic fibrosis transmembrane conductance regulator variants that have been laboratory established in the family history, not being a service associated with a service to which item 73345, 73347, or 73349 applies. The patient must have a positive family history, confirmed by laboratory findings of pathogenic cystic fibrosis transmembrane conductance regulator variants, with a personal risk of being a heterozygous genetic carrier of at least 6%. (This includes family relatedness of: parents, children, full-siblings, half-siblings, grand-parents, grandchildren, aunts, uncles, first cousins, and first cousins once-removed, but excludes relatedness of second cousins or more distant relationships). Group P7	Category 6 — Pathology	$250.00	—
Item Number 73348 Schedule Fee $250.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2018 Item from: 01.07.2018 Gov. Change Flags No changes flagged Full Description Testing of a patient with a laboratory-established family history of pathogenic cystic fibrosis transmembrane conductance regulator variants, for the purpose of determining whether the patient is an asymptomatic genetic carrier of the pathogenic cystic fibrosis transmembrane conductance regulator variants that have been laboratory established in the family history, not being a service associated with a service to which item 73345, 73347, or 73349 applies. The patient must have a positive family history, confirmed by laboratory findings of pathogenic cystic fibrosis transmembrane conductance regulator variants, with a personal risk of being a heterozygous genetic carrier of at least 6%. (This includes family relatedness of: parents, children, full-siblings, half-siblings, grand-parents, grandchildren, aunts, uncles, first cousins, and first cousins once-removed, but excludes relatedness of second cousins or more distant relationships). Sign in to watch this code → Get an email alert when this item changes
	73349	Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the reproductive risk of the patient with their reproductive partner because their reproductive partner is already known to have pathogenic cystic fibrosis transmembrane conductance regulator variants requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73347, or 73348 applies. Group P7	Category 6 — Pathology	$500.00	—
Item Number 73349 Schedule Fee $500.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2018 Item from: 01.07.2018 Gov. Change Flags No changes flagged Full Description Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the reproductive risk of the patient with their reproductive partner because their reproductive partner is already known to have pathogenic cystic fibrosis transmembrane conductance regulator variants requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73347, or 73348 applies. Sign in to watch this code → Get an email alert when this item changes
	73350	Testing of a pregnant patient, where one or both prospective parents are known to be a genetic carrier of pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus, when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73346 applies. The fetus must be at 25% or more risk of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder because of known familial cystic fibrosis transmembrane conductance regulator variants. Group P7	Category 6 — Pathology	$250.00	—
Item Number 73350 Schedule Fee $250.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2018 Item from: 01.07.2018 Gov. Change Flags No changes flagged Full Description Testing of a pregnant patient, where one or both prospective parents are known to be a genetic carrier of pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus, when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73346 applies. The fetus must be at 25% or more risk of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder because of known familial cystic fibrosis transmembrane conductance regulator variants. Sign in to watch this code → Get an email alert when this item changes
	73351	A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled. Group P7	Category 6 — Pathology	$397.35	—
Item Number 73351 Schedule Fee $397.35 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.02.2019 Item from: 01.02.2019 Gov. Change Flags No changes flagged Full Description A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled. Sign in to watch this code → Get an email alert when this item changes
	73352	Characterisation of germline variants causing familial hypercholesterolaemia (which must include the LDLR, PCSK9 and APOB genes), requested by a specialist or consultant physician, for a patient: (a) for whom no familial mutation has been identified; and (b) who has any of the following: (i) a Dutch Lipid Clinic Network score of at least 6; (ii) an LDL-cholesterol level of at least 6.5 mmol/L in the absence of secondary causes; (iii) an LDL-cholesterol level of between 5.0 and 6.5 mmol/L with signs of premature or accelerated atherogenesis Applicable only once per lifetime Group P7	Category 6 — Pathology	$1200.00	—
Item Number 73352 Schedule Fee $1200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Characterisation of germline variants causing familial hypercholesterolaemia (which must include the LDLR, PCSK9 and APOB genes), requested by a specialist or consultant physician, for a patient: (a) for whom no familial mutation has been identified; and (b) who has any of the following: (i) a Dutch Lipid Clinic Network score of at least 6; (ii) an LDL-cholesterol level of at least 6.5 mmol/L in the absence of secondary causes; (iii) an LDL-cholesterol level of between 5.0 and 6.5 mmol/L with signs of premature or accelerated atherogenesis Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73353	Detection of a familial mutation for a patient who has a first- or second-degree relative with a documented pathogenic germline gene variant for familial hypercholesterolaemia Applicable only once per lifetime Group P7	Category 6 — Pathology	$400.00	—
Item Number 73353 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Detection of a familial mutation for a patient who has a first- or second-degree relative with a documented pathogenic germline gene variant for familial hypercholesterolaemia Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73354	Characterisation of germline gene variants, including copy number variation, in the MLH1, MSH2, MSH6, PMS2 and EPCAM genes, requested by a specialist or consultant physician, for:(a) a patient with suspected Lynch syndrome following immunohistochemical examination of neoplastic tissue that has demonstrated loss of expression of one or more mismatch repair proteins; or (b) a patient: (i) who has endometrial cancer; and (ii) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having Lynch syndrome, on the basis of clinical and family history criteria Group P7	Category 6 — Pathology	$1200.00	—
Item Number 73354 Schedule Fee $1200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Characterisation of germline gene variants, including copy number variation, in the MLH1, MSH2, MSH6, PMS2 and EPCAM genes, requested by a specialist or consultant physician, for:(a) a patient with suspected Lynch syndrome following immunohistochemical examination of neoplastic tissue that has demonstrated loss of expression of one or more mismatch repair proteins; or (b) a patient: (i) who has endometrial cancer; and (ii) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having Lynch syndrome, on the basis of clinical and family history criteria Sign in to watch this code → Get an email alert when this item changes
	73355	Characterisation of germline gene variants, including copy number variation, in the APC and MUTYH genes, requested by a specialist or consultant physician, for a patient: (a) who has adenomatous polyposis; and (b) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having either of the following, on the basis of clinical and family history criteria: (i) familial adenomatous polyposis; (ii) MUTYH-associated polyposis Group P7	Category 6 — Pathology	$1200.00	—
Item Number 73355 Schedule Fee $1200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Characterisation of germline gene variants, including copy number variation, in the APC and MUTYH genes, requested by a specialist or consultant physician, for a patient: (a) who has adenomatous polyposis; and (b) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having either of the following, on the basis of clinical and family history criteria: (i) familial adenomatous polyposis; (ii) MUTYH-associated polyposis Sign in to watch this code → Get an email alert when this item changes
	73356	Characterisation of germline gene variants, including copy number variation, in the SMAD4, BMPR1A, STK11 and GREM1 genes, requested by a specialist or consultant physician, for a patient: (a) who has non-adenomatous polyposis; and (b) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having any of the following, on the basis of clinical and family history criteria: (i) juvenile polyposis syndrome; (ii) Peutz-Jeghers syndrome; (iii) hereditary mixed polyposis syndrome Group P7	Category 6 — Pathology	$1200.00	—
Item Number 73356 Schedule Fee $1200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Characterisation of germline gene variants, including copy number variation, in the SMAD4, BMPR1A, STK11 and GREM1 genes, requested by a specialist or consultant physician, for a patient: (a) who has non-adenomatous polyposis; and (b) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having any of the following, on the basis of clinical and family history criteria: (i) juvenile polyposis syndrome; (ii) Peutz-Jeghers syndrome; (iii) hereditary mixed polyposis syndrome Sign in to watch this code → Get an email alert when this item changes
	73357	Characterisation of germline gene variants, including copy number variation, in the genes mentioned in item 73354, 73355 or 73356, requested by a specialist or consultant physician, for a patient: (a) who has a biological relative with a pathogenic mutation identified in one or more of those genes; and (b) who has not previously received a service to which any of items 73354, 73355 and 73356 apply Group P7	Category 6 — Pathology	$400.00	—
Item Number 73357 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Characterisation of germline gene variants, including copy number variation, in the genes mentioned in item 73354, 73355 or 73356, requested by a specialist or consultant physician, for a patient: (a) who has a biological relative with a pathogenic mutation identified in one or more of those genes; and (b) who has not previously received a service to which any of items 73354, 73355 and 73356 apply Sign in to watch this code → Get an email alert when this item changes
	73358	Characterisation, via whole exome or genome sequencing and analysis, of germline variants known to cause monogenic disorders, if: (a) the characterisation is: (i) requested by a consultant physician practising as a clinical geneticist; or (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and (b) the patient is aged 10 years or younger and is strongly suspected of having a monogenic condition, based on the presence of: (i) dysmorphic facial appearance and one or more major structural congenital anomalies; or (ii) intellectual disability or global developmental delay of at least moderate severity, as determined by a specialist paediatrician; and (c) the characterisation is performed following the performance for the patient of a service to which item 73292 applies for which the results were non-informative; and (d) the characterisation is not performed in conjunction with a service to which item 73359 applies Applicable only once per lifetime Group P7	Category 6 — Pathology	$2100.00	—
Item Number 73358 Schedule Fee $2100.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Characterisation, via whole exome or genome sequencing and analysis, of germline variants known to cause monogenic disorders, if: (a) the characterisation is: (i) requested by a consultant physician practising as a clinical geneticist; or (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and (b) the patient is aged 10 years or younger and is strongly suspected of having a monogenic condition, based on the presence of: (i) dysmorphic facial appearance and one or more major structural congenital anomalies; or (ii) intellectual disability or global developmental delay of at least moderate severity, as determined by a specialist paediatrician; and (c) the characterisation is performed following the performance for the patient of a service to which item 73292 applies for which the results were non-informative; and (d) the characterisation is not performed in conjunction with a service to which item 73359 applies Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73359	Characterisation, via whole exome or genome sequencing and analysis, of germline variants known to cause monogenic disorders, if: (a) the characterisation is: (i) requested by a consultant physician practising as a clinical geneticist; or (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and (b) the request for the characterisation states that singleton testing is inappropriate; and (c) the patient is aged 10 years or younger and is strongly suspected of having a monogenic condition, based on the presence of: (i) dysmorphic facial appearance and one or more major structural congenital anomalies; or (ii) intellectual disability or global developmental delay of at least moderate severity, as determined by a specialist paediatrician; and (d) the characterisation is performed following the performance for the patient of a service to which item 73292 applies for which the results were non-informative; and (e) the characterisation is performed using a sample from the patient and a sample from each of the patient’s biological parents; and (f) the characterisation is not performed in conjunction with a service to which item 73358 applies Applicable only once per lifetime Group P7	Category 6 — Pathology	$2900.00	—
Item Number 73359 Schedule Fee $2900.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Characterisation, via whole exome or genome sequencing and analysis, of germline variants known to cause monogenic disorders, if: (a) the characterisation is: (i) requested by a consultant physician practising as a clinical geneticist; or (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and (b) the request for the characterisation states that singleton testing is inappropriate; and (c) the patient is aged 10 years or younger and is strongly suspected of having a monogenic condition, based on the presence of: (i) dysmorphic facial appearance and one or more major structural congenital anomalies; or (ii) intellectual disability or global developmental delay of at least moderate severity, as determined by a specialist paediatrician; and (d) the characterisation is performed following the performance for the patient of a service to which item 73292 applies for which the results were non-informative; and (e) the characterisation is performed using a sample from the patient and a sample from each of the patient’s biological parents; and (f) the characterisation is not performed in conjunction with a service to which item 73358 applies Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73360	Re-analysis of whole exome or genome data obtained in performing a service to which item 73358 or 73359 applies, for characterisation of previously unreported germline gene variants related to the clinical phenotype, if: (a) the re-analysis is: (i) requested by a consultant physician practising as a clinical geneticist; or (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and (b) the patient is aged 15 years or younger and is strongly suspected of having a monogenic condition; and (c) the re-analysis is performed at least 18 months after: (i) a service to which item 73358 or 73359 applies; or (ii) a service to which this item applies Applicable only twice per lifetime Group P7	Category 6 — Pathology	$500.00	—
Item Number 73360 Schedule Fee $500.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Re-analysis of whole exome or genome data obtained in performing a service to which item 73358 or 73359 applies, for characterisation of previously unreported germline gene variants related to the clinical phenotype, if: (a) the re-analysis is: (i) requested by a consultant physician practising as a clinical geneticist; or (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and (b) the patient is aged 15 years or younger and is strongly suspected of having a monogenic condition; and (c) the re-analysis is performed at least 18 months after: (i) a service to which item 73358 or 73359 applies; or (ii) a service to which this item applies Applicable only twice per lifetime Sign in to watch this code → Get an email alert when this item changes
	73361	Testing of a person (the person tested) for the detection of a single gene variant for diagnostic purposes, if: the person tested has a biological sibling (the sibling) with a known monogenic condition; and a service described in item 73358, 73359 or 73360 has identified the causative variant for the sibling’s condition; and the results of the testing performed for the sibling are made available for the purpose of providing the detection for the person tested; and the detection is: requested by a consultant physician practising as a clinical geneticist; or requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and the detection is not performed in conjunction with a service to which item 73362 or 73363 applies Applicable only once per variant per lifetime Group P7	Category 6 — Pathology	$400.00	—
Item Number 73361 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Testing of a person (the person tested) for the detection of a single gene variant for diagnostic purposes, if: the person tested has a biological sibling (the sibling) with a known monogenic condition; and a service described in item 73358, 73359 or 73360 has identified the causative variant for the sibling’s condition; and the results of the testing performed for the sibling are made available for the purpose of providing the detection for the person tested; and the detection is: requested by a consultant physician practising as a clinical geneticist; or requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and the detection is not performed in conjunction with a service to which item 73362 or 73363 applies Applicable only once per variant per lifetime Sign in to watch this code → Get an email alert when this item changes
	73362	Testing of a person (the person tested) for the detection of a single gene variant for the purpose of reproductive decision making, if: the person tested has a first‑degree relative (the relative) with a known monogenic condition; and a service described in item 73358, 73359 or 73360 has identified the causative variant for the relative’s condition; and the results of the testing performed for the relative are made available for the purpose of providing the detection for the person tested; and the detection is requested by a consultant physician or specialist; and the detection is not performed in conjunction with item 73359, 73361 or 73363 Applicable only once per variant per lifetime Group P7	Category 6 — Pathology	$400.00	—
Item Number 73362 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Testing of a person (the person tested) for the detection of a single gene variant for the purpose of reproductive decision making, if: the person tested has a first‑degree relative (the relative) with a known monogenic condition; and a service described in item 73358, 73359 or 73360 has identified the causative variant for the relative’s condition; and the results of the testing performed for the relative are made available for the purpose of providing the detection for the person tested; and the detection is requested by a consultant physician or specialist; and the detection is not performed in conjunction with item 73359, 73361 or 73363 Applicable only once per variant per lifetime Sign in to watch this code → Get an email alert when this item changes
	73363	Testing of a person (the person tested) for the detection of a single gene variant for segregation analysis in relation to another person (the patient), if: the patient has a known phenotype of a suspected monogenic condition; and a service described in item 73358 or 73360 has identified a potentially causative variant for the patient; and the person tested is a biological parent or other biological relative of the patient; and a sample from the person tested has not previously been tested in relation to the patient for a service to which item 73359 applies; and the results of the testing of the person tested for this service are made available for the purpose of providing the detection for the patient; and the detection is: requested by a consultant physician practising as a clinical geneticist; or requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and the detection is not performed in conjunction with item 73361 or 73362 Applicable only once per variant per lifetime Group P7	Category 6 — Pathology	$400.00	—
Item Number 73363 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Testing of a person (the person tested) for the detection of a single gene variant for segregation analysis in relation to another person (the patient), if: the patient has a known phenotype of a suspected monogenic condition; and a service described in item 73358 or 73360 has identified a potentially causative variant for the patient; and the person tested is a biological parent or other biological relative of the patient; and a sample from the person tested has not previously been tested in relation to the patient for a service to which item 73359 applies; and the results of the testing of the person tested for this service are made available for the purpose of providing the detection for the patient; and the detection is: requested by a consultant physician practising as a clinical geneticist; or requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and the detection is not performed in conjunction with item 73361 or 73362 Applicable only once per variant per lifetime Sign in to watch this code → Get an email alert when this item changes
	73364	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for: (i) the characterisation of MYC gene rearrangement; and (ii) if the results of the characterisation mentioned in subparagraph (i) are positive—the characterisation of either or both of BCL2 gene rearrangement and BCL6 gene rearrangement; and (b) is for a patient: (i) for whom MYC immunohistochemistry is non-negative; and (ii) with clinical or laboratory evidence, including morphological features, of diffuse large B-cell lymphoma or high grade B-cell lymphoma; and (c) is not performed in conjunction with item 73365 Applicable only once per lifetime Group P7	Category 6 — Pathology	$400.00	—
Item Number 73364 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for: (i) the characterisation of MYC gene rearrangement; and (ii) if the results of the characterisation mentioned in subparagraph (i) are positive—the characterisation of either or both of BCL2 gene rearrangement and BCL6 gene rearrangement; and (b) is for a patient: (i) for whom MYC immunohistochemistry is non-negative; and (ii) with clinical or laboratory evidence, including morphological features, of diffuse large B-cell lymphoma or high grade B-cell lymphoma; and (c) is not performed in conjunction with item 73365 Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73365	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of MYC gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of Burkitt lymphoma; and (c) is not performed in conjunction with item 73364 Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73365 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of MYC gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of Burkitt lymphoma; and (c) is not performed in conjunction with item 73364 Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73366	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of either or both of the following: (i) CCND1 gene rearrangement; (ii) CCND2 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of mantle cell lymphoma Applicable only once per lifetime Group P7	Category 6 — Pathology	$400.00	—
Item Number 73366 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of either or both of the following: (i) CCND1 gene rearrangement; (ii) CCND2 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of mantle cell lymphoma Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73367	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the presence of isochromosome 7q; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of hepatosplenic T‑cell lymphoma Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73367 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the presence of isochromosome 7q; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of hepatosplenic T‑cell lymphoma Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73368	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of either or both of the following: (i) DUSP22 gene rearrangement; (ii) TP63 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of ALK negative anaplastic large cell lymphoma Applicable only once per lifetime Group P7	Category 6 — Pathology	$400.00	—
Item Number 73368 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of either or both of the following: (i) DUSP22 gene rearrangement; (ii) TP63 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of ALK negative anaplastic large cell lymphoma Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73369	Analysis of blood or bone marrow, requested by a specialist or consultant physician, that: (a) is for the characterisation of either or both of the following: (i) TCL1A gene rearrangement; (ii) MTCP1 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of T‑cell prolymphocytic leukaemia Applicable only once per lifetime Group P7	Category 6 — Pathology	$400.00	—
Item Number 73369 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of blood or bone marrow, requested by a specialist or consultant physician, that: (a) is for the characterisation of either or both of the following: (i) TCL1A gene rearrangement; (ii) MTCP1 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of T‑cell prolymphocytic leukaemia Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73370	Analysis of blood or bone marrow, requested by a specialist or consultant physician, that: (a) is for the characterisation of the following: (i) chromosome translocations t(4;14), t(14;16), t(14;20); (ii) 1q gain; (iii) 17p deletion; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of plasma cell myeloma Applicable only once per lifetime Group P7	Category 6 — Pathology	$500.00	—
Item Number 73370 Schedule Fee $500.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of blood or bone marrow, requested by a specialist or consultant physician, that: (a) is for the characterisation of the following: (i) chromosome translocations t(4;14), t(14;16), t(14;20); (ii) 1q gain; (iii) 17p deletion; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of plasma cell myeloma Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73371	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the detection of chromosome 1p/19q co‑deletion; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of glial neoplasm with probable oligodendroglial component Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73371 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the detection of chromosome 1p/19q co‑deletion; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of glial neoplasm with probable oligodendroglial component Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73372	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the identification of IDH1/2 pathological variant status; and (b) is for a patient with: (i) negative IDH1 (R132H) immunohistochemistry; and (ii) clinical or laboratory evidence, including morphological features, of glial neoplasm Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73372 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the identification of IDH1/2 pathological variant status; and (b) is for a patient with: (i) negative IDH1 (R132H) immunohistochemistry; and (ii) clinical or laboratory evidence, including morphological features, of glial neoplasm Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73373	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of MGMT promoter methylation status; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of glioblastoma Applicable only once per lifetime Group P7	Category 6 — Pathology	$400.00	—
Item Number 73373 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of MGMT promoter methylation status; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of glioblastoma Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73374	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of copy number changes, gene rearrangements, or other molecular changes in genes associated with sarcoma; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of sarcoma— analysis in relation to only one gene Applicable once per tumour diagnostic episode Group P7	Category 6 — Pathology	$340.00	—
Item Number 73374 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of copy number changes, gene rearrangements, or other molecular changes in genes associated with sarcoma; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of sarcoma— analysis in relation to only one gene Applicable once per tumour diagnostic episode Sign in to watch this code → Get an email alert when this item changes
	73375	An analysis described in item 73374—analysis in relation to only 2 or 3 genes Applicable once per tumour diagnostic episode Group P7	Category 6 — Pathology	$400.00	—
Item Number 73375 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description An analysis described in item 73374—analysis in relation to only 2 or 3 genes Applicable once per tumour diagnostic episode Sign in to watch this code → Get an email alert when this item changes
	73376	An analysis described in item 73374—analysis in relation to 4 or more genes Applicable once per tumour diagnostic episode Group P7	Category 6 — Pathology	$800.00	—
Item Number 73376 Schedule Fee $800.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description An analysis described in item 73374—analysis in relation to 4 or more genes Applicable once per tumour diagnostic episode Sign in to watch this code → Get an email alert when this item changes
	73377	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the detection of FOXL2.402C>G status; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of granulosa cell ovarian tumour Applicable only once per lifetime Group P7	Category 6 — Pathology	$250.00	—
Item Number 73377 Schedule Fee $250.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the detection of FOXL2.402C>G status; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of granulosa cell ovarian tumour Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73378	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of NUTM1 gene status at 15q14; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of midline NUT carcinoma Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73378 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of NUTM1 gene status at 15q14; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of midline NUT carcinoma Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73379	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of ETV6‑NTRK3 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of secretory carcinoma of the breast Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73379 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of ETV6‑NTRK3 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of secretory carcinoma of the breast Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73380	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of MAML2 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of mucoepidermoid carcinoma Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73380 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of MAML2 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of mucoepidermoid carcinoma Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73381	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of ETV6‑NTRK3 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of mammary analogue secretory carcinoma of the salivary gland Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73381 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of ETV6‑NTRK3 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of mammary analogue secretory carcinoma of the salivary gland Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73382	Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of EWSR1 gene rearrangement, with or without PLAG1 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of hyalinising clear cell carcinoma of the salivary gland Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73382 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2020 Item from: 01.05.2020 Gov. Change Flags No changes flagged Full Description Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of EWSR1 gene rearrangement, with or without PLAG1 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of hyalinising clear cell carcinoma of the salivary gland Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes

Fee From

01.11.2012

Category

Category 6 — Pathology

Description

Detection of germline mutations of the von Hippel‑Lindau (VHL) gene: (a) in a patient who has a clinical diagnosis of VHL syndrome and: (i) a family history of VHL syndrome and one of the following: (A) haemangioblastoma (retinal or central nervous system); (B) phaeochromocytoma; (C) renal cell carcinoma; or (ii) 2 or more haemangioblastomas; or (iii) one haemangioblastoma and a tumour or a cyst of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; or (E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or (b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome: (i) haemangiblastomas of the brain, spinal cord, or retina; (ii) phaeochromocytoma; (iii) functional extra‑adrenal paraganglioma

Fee From

01.11.2012

Category

Category 6 — Pathology

Description

Detection of germline mutations of the von Hippel-Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene

Fee From

01.11.2012

Category

Category 6 — Pathology

Description

Detection of somatic mutations of the von Hippel-Lindau (VHL) gene in a patient with: (a) 2 or more tumours comprising: (i) 2 or more haemangioblastomas, or (ii) one haemangioblastoma and a tumour of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; and (b) no germline mutations of the VHL gene identified by genetic testing

Fee From

01.12.2013

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.

Fee From

01.01.2014

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) for epidermal growth factor receptor (EGFR) status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73438 applies

Fee From

22.08.2016

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if: (a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if: the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or a clinically-relevant RAS variant is detected; and, in cases where no RAS variant is detected (b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.

Fee From

01.11.2014

Category

Category 6 — Pathology

Description

Detection of germline mutations in the RET gene in patients with a suspected clinical diagnosis of multiple endocrine neoplasia type 2 (MEN2) requested by a specialist or consultant physician who manages the treatment of the patient. One test. (Item is subject to rule 25)

Fee From

01.11.2014

Category

Category 6 — Pathology

Description

Detection of a known mutation in the RET gene in an asymptomatic relative of a patient with a documented pathogenic germline RET mutation requested by a specialist or consultant physician who manages the treatment of the patient. One test. (Item is subject to rule 25)

Fee From

01.07.2015

Category

Category 6 — Pathology

Description

Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is: (a) for ALK gene rearrangement status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73439 applies

Fee From

01.01.2016

Category

Category 6 — Pathology

Description

An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled.

Fee From

01.11.2021

Category

Category 6 — Pathology

Description

Detection of 17p chromosomal deletions, in a patient with chronic lymphocytic leukaemia or small lymphocytic lymphoma, on a peripheral blood, bone marrow or lymph node sample, requested by a specialist or consultant physician For any particular patient: (a) at initial diagnosis; or (b) at disease relapse; or (c) on disease progression; but only where initiation of, or change in, therapy is anticipated

Fee From

01.01.2019

Category

Category 6 — Pathology

Description

Fluorescence in situ hybridization (FISH) test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by a specialist or consultant physician, if the test is: (a) for ROS1 gene arrangement status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73439 applies

Fee From

01.07.2018

Category

Category 6 — Pathology

Description

Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of investigating, making or excluding a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73347, 73348, or 73349 applies. The patient must have clinical or laboratory findings suggesting there is a high probability suggestive of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder.

Fee From

01.07.2018

Category

Category 6 — Pathology

Description

Testing of a pregnant patient whose carrier status for pathogenic cystic fibrosis transmembrane conductance regulator variants, as well as their reproductive partner carrier status is unknown, for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus, in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73350 applies. The fetus must have ultrasonic findings of echogenic gut, with unknown familial cystic fibrosis transmembrane conductance regulator variants.

Fee From

01.07.2018

Category

Category 6 — Pathology

Description

Testing of a prospective parent for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the risk of their fetus having pathogenic cystic fibrosis transmembrane conductance regulator variants. This is indicated when the fetus has ultrasonic evidence of echogenic gut when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73348, or 73349 applies.

Fee From

01.07.2018

Category

Category 6 — Pathology

Description

Testing of a patient with a laboratory-established family history of pathogenic cystic fibrosis transmembrane conductance regulator variants, for the purpose of determining whether the patient is an asymptomatic genetic carrier of the pathogenic cystic fibrosis transmembrane conductance regulator variants that have been laboratory established in the family history, not being a service associated with a service to which item 73345, 73347, or 73349 applies. The patient must have a positive family history, confirmed by laboratory findings of pathogenic cystic fibrosis transmembrane conductance regulator variants, with a personal risk of being a heterozygous genetic carrier of at least 6%. (This includes family relatedness of: parents, children, full-siblings, half-siblings, grand-parents, grandchildren, aunts, uncles, first cousins, and first cousins once-removed, but excludes relatedness of second cousins or more distant relationships).

Fee From

01.07.2018

Category

Category 6 — Pathology

Description

Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the reproductive risk of the patient with their reproductive partner because their reproductive partner is already known to have pathogenic cystic fibrosis transmembrane conductance regulator variants requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73347, or 73348 applies.

Fee From

01.07.2018

Category

Category 6 — Pathology

Description

Testing of a pregnant patient, where one or both prospective parents are known to be a genetic carrier of pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus, when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73346 applies. The fetus must be at 25% or more risk of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder because of known familial cystic fibrosis transmembrane conductance regulator variants.

Fee From

01.02.2019

Category

Category 6 — Pathology

Description

A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled.

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Characterisation of germline variants causing familial hypercholesterolaemia (which must include the LDLR, PCSK9 and APOB genes), requested by a specialist or consultant physician, for a patient: (a) for whom no familial mutation has been identified; and (b) who has any of the following: (i) a Dutch Lipid Clinic Network score of at least 6; (ii) an LDL-cholesterol level of at least 6.5 mmol/L in the absence of secondary causes; (iii) an LDL-cholesterol level of between 5.0 and 6.5 mmol/L with signs of premature or accelerated atherogenesis Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Detection of a familial mutation for a patient who has a first- or second-degree relative with a documented pathogenic germline gene variant for familial hypercholesterolaemia Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants, including copy number variation, in the MLH1, MSH2, MSH6, PMS2 and EPCAM genes, requested by a specialist or consultant physician, for:(a) a patient with suspected Lynch syndrome following immunohistochemical examination of neoplastic tissue that has demonstrated loss of expression of one or more mismatch repair proteins; or (b) a patient: (i) who has endometrial cancer; and (ii) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having Lynch syndrome, on the basis of clinical and family history criteria

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants, including copy number variation, in the APC and MUTYH genes, requested by a specialist or consultant physician, for a patient: (a) who has adenomatous polyposis; and (b) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having either of the following, on the basis of clinical and family history criteria: (i) familial adenomatous polyposis; (ii) MUTYH-associated polyposis

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants, including copy number variation, in the SMAD4, BMPR1A, STK11 and GREM1 genes, requested by a specialist or consultant physician, for a patient: (a) who has non-adenomatous polyposis; and (b) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having any of the following, on the basis of clinical and family history criteria: (i) juvenile polyposis syndrome; (ii) Peutz-Jeghers syndrome; (iii) hereditary mixed polyposis syndrome

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants, including copy number variation, in the genes mentioned in item 73354, 73355 or 73356, requested by a specialist or consultant physician, for a patient: (a) who has a biological relative with a pathogenic mutation identified in one or more of those genes; and (b) who has not previously received a service to which any of items 73354, 73355 and 73356 apply

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Characterisation, via whole exome or genome sequencing and analysis, of germline variants known to cause monogenic disorders, if: (a) the characterisation is: (i) requested by a consultant physician practising as a clinical geneticist; or (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and (b) the patient is aged 10 years or younger and is strongly suspected of having a monogenic condition, based on the presence of: (i) dysmorphic facial appearance and one or more major structural congenital anomalies; or (ii) intellectual disability or global developmental delay of at least moderate severity, as determined by a specialist paediatrician; and (c) the characterisation is performed following the performance for the patient of a service to which item 73292 applies for which the results were non-informative; and (d) the characterisation is not performed in conjunction with a service to which item 73359 applies Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Characterisation, via whole exome or genome sequencing and analysis, of germline variants known to cause monogenic disorders, if: (a) the characterisation is: (i) requested by a consultant physician practising as a clinical geneticist; or (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and (b) the request for the characterisation states that singleton testing is inappropriate; and (c) the patient is aged 10 years or younger and is strongly suspected of having a monogenic condition, based on the presence of: (i) dysmorphic facial appearance and one or more major structural congenital anomalies; or (ii) intellectual disability or global developmental delay of at least moderate severity, as determined by a specialist paediatrician; and (d) the characterisation is performed following the performance for the patient of a service to which item 73292 applies for which the results were non-informative; and (e) the characterisation is performed using a sample from the patient and a sample from each of the patient’s biological parents; and (f) the characterisation is not performed in conjunction with a service to which item 73358 applies Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Re-analysis of whole exome or genome data obtained in performing a service to which item 73358 or 73359 applies, for characterisation of previously unreported germline gene variants related to the clinical phenotype, if: (a) the re-analysis is: (i) requested by a consultant physician practising as a clinical geneticist; or (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and (b) the patient is aged 15 years or younger and is strongly suspected of having a monogenic condition; and (c) the re-analysis is performed at least 18 months after: (i) a service to which item 73358 or 73359 applies; or (ii) a service to which this item applies Applicable only twice per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Testing of a person (the person tested) for the detection of a single gene variant for diagnostic purposes, if: the person tested has a biological sibling (the sibling) with a known monogenic condition; and a service described in item 73358, 73359 or 73360 has identified the causative variant for the sibling’s condition; and the results of the testing performed for the sibling are made available for the purpose of providing the detection for the person tested; and the detection is: requested by a consultant physician practising as a clinical geneticist; or requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and the detection is not performed in conjunction with a service to which item 73362 or 73363 applies Applicable only once per variant per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Testing of a person (the person tested) for the detection of a single gene variant for the purpose of reproductive decision making, if: the person tested has a first‑degree relative (the relative) with a known monogenic condition; and a service described in item 73358, 73359 or 73360 has identified the causative variant for the relative’s condition; and the results of the testing performed for the relative are made available for the purpose of providing the detection for the person tested; and the detection is requested by a consultant physician or specialist; and the detection is not performed in conjunction with item 73359, 73361 or 73363 Applicable only once per variant per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Testing of a person (the person tested) for the detection of a single gene variant for segregation analysis in relation to another person (the patient), if: the patient has a known phenotype of a suspected monogenic condition; and a service described in item 73358 or 73360 has identified a potentially causative variant for the patient; and the person tested is a biological parent or other biological relative of the patient; and a sample from the person tested has not previously been tested in relation to the patient for a service to which item 73359 applies; and the results of the testing of the person tested for this service are made available for the purpose of providing the detection for the patient; and the detection is: requested by a consultant physician practising as a clinical geneticist; or requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and the detection is not performed in conjunction with item 73361 or 73362 Applicable only once per variant per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for: (i) the characterisation of MYC gene rearrangement; and (ii) if the results of the characterisation mentioned in subparagraph (i) are positive—the characterisation of either or both of BCL2 gene rearrangement and BCL6 gene rearrangement; and (b) is for a patient: (i) for whom MYC immunohistochemistry is non-negative; and (ii) with clinical or laboratory evidence, including morphological features, of diffuse large B-cell lymphoma or high grade B-cell lymphoma; and (c) is not performed in conjunction with item 73365 Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of MYC gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of Burkitt lymphoma; and (c) is not performed in conjunction with item 73364 Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of either or both of the following: (i) CCND1 gene rearrangement; (ii) CCND2 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of mantle cell lymphoma Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the presence of isochromosome 7q; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of hepatosplenic T‑cell lymphoma Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of either or both of the following: (i) DUSP22 gene rearrangement; (ii) TP63 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of ALK negative anaplastic large cell lymphoma Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of blood or bone marrow, requested by a specialist or consultant physician, that: (a) is for the characterisation of either or both of the following: (i) TCL1A gene rearrangement; (ii) MTCP1 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of T‑cell prolymphocytic leukaemia Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of blood or bone marrow, requested by a specialist or consultant physician, that: (a) is for the characterisation of the following: (i) chromosome translocations t(4;14), t(14;16), t(14;20); (ii) 1q gain; (iii) 17p deletion; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of plasma cell myeloma Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the detection of chromosome 1p/19q co‑deletion; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of glial neoplasm with probable oligodendroglial component Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the identification of IDH1/2 pathological variant status; and (b) is for a patient with: (i) negative IDH1 (R132H) immunohistochemistry; and (ii) clinical or laboratory evidence, including morphological features, of glial neoplasm Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of MGMT promoter methylation status; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of glioblastoma Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of copy number changes, gene rearrangements, or other molecular changes in genes associated with sarcoma; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of sarcoma— analysis in relation to only one gene Applicable once per tumour diagnostic episode

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

An analysis described in item 73374—analysis in relation to only 2 or 3 genes Applicable once per tumour diagnostic episode

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

An analysis described in item 73374—analysis in relation to 4 or more genes Applicable once per tumour diagnostic episode

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the detection of FOXL2.402C>G status; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of granulosa cell ovarian tumour Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of NUTM1 gene status at 15q14; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of midline NUT carcinoma Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of ETV6‑NTRK3 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of secretory carcinoma of the breast Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of MAML2 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of mucoepidermoid carcinoma Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of ETV6‑NTRK3 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of mammary analogue secretory carcinoma of the salivary gland Applicable only once per lifetime

Fee From

01.05.2020

Category

Category 6 — Pathology

Description

Analysis of tumour tissue, requested by a specialist or consultant physician, that: (a) is for the characterisation of EWSR1 gene rearrangement, with or without PLAG1 gene rearrangement; and (b) is for a patient with clinical or laboratory evidence, including morphological features, of hyalinising clear cell carcinoma of the salivary gland Applicable only once per lifetime

← Prev 103 104 105 106 107 Next →

50 items per page · tap/click any row to expand

MBS Item Tracker